New Birth Control Pills May Reduce Ovarian Cancer Risk

New birth control pills can lower the risk of developing ovarian cancer, reveals a new study.

New birth control pills can cut ovarian cancer risk, reports a new study. The findings of the study are published in the journal The BMJ.

New types of combined birth control pills -- containing both lower doses of estrogens and newer progestogens may reduce the risk of ovarian cancer among young women, says a study.

Ovarian Cancer | Cancer in the Ovaries - Causes, Symptoms, Treatment & Prevention
Ovarian cancer affects both the ovaries and is referred to as the 'silent killer' as the symptoms go unnoticed until the disease advances.

‘New birth control pills can help lower the risk of developing ovarian cancer.’

The study showed that this positive effect strengthened with longer periods of use and persisted for several years after stopping.

"The reduced risk seems to persist after stopping use, although the duration of benefit is uncertain," the study said.

At least 100 million women worldwide use hormonal contraception every day.

Calcitriol May Improve Chances of Survival in Ovarian Cancer
New ovarian cancer target has been identified by experts at the Houston Methodist Cancer Center. Preclinical research shows that malignant cells are linked to supportive fibroblasts and they can be hit with Calcitriol.

For the study, the researchers from the University of Aberdeen in Scotland and the University of Copenhagen in Denmark analyzed data for nearly 1.9 million Danish women aged 15-49 years between 1995 and 2014.

Women were categorized as never users (no record of being dispensed hormonal contraception), current or recent users (up to one year after stopping use), or former users (more than one year after stopping use) of different hormonal contraceptives.

Ovarian Cancer May Originate In The Fallopian Tubes
Mutation in Fallopian tube lesions may help catch ovarian cancer years earlier. Driven by TP53 mutation, tube lesions evolved into ovarian cancer Penn study says

Most (86 percent) of the hormonal contraceptive use related to combined oral products.

The researchers found that the number of cases of ovarian cancer were highest in women who had never used hormonal contraception (7.5 per 100,000 person years), whereas, among women who had ever used hormonal contraception, the number of cases of ovarian cancer were 3.2 per 100,000 person years.

Rucaparib Beneficial as Maintenance Treatment for Recurrent Ovarian Cancer
The ARIEL3 trial demonstrated the benefit of rucaparib as maintenance treatment in women with platinum-sensitive, recurrent ovarian cancer, especially in BRCA mutant cases.

The reduced risk for combined products was seen with nearly all types of ovarian cancer, and there was little evidence of important differences between products containing different types of progestogens.

"Based on our results, contemporary combined hormonal contraceptives are still associated with a reduced risk of ovarian cancer in women of reproductive age, with patterns similar to those seen with older combined oral products," the study authors said.

Previous research had shown that the older products, containing higher levels of estrogen and older progestogens, were tied to reduced ovarian cancer risk.

But it was not known whether the newer contraceptives carried the same benefit.

Source-IANS